Pharma Companies Announce “Discontinuation Of ENGAGE And EMERGE Programmes
Pharmaceutical companies Biogen and Eisai have announced the discontinuation of two Phase 3 trials of aducanumab. The decision came after analysis by an independent monitoring…
Read more...